Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041)

被引：0
|
作者：
Van Herpen, C.
Fiedler, W.
Toma, S.
Marreaud, S.
Van Laarhoven, H.
Lasch, P.
Bogaerts, J.
Heerschap, A.
Bordignon, C.
Punt, C.
机构：
[1] Radboud Univ Nijmegen Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[2] Univ Hosp Hamburg Eppendorf, Dept Med 2, Hamburg, Germany
[3] Molmed, Milan, Italy
[4] EORTC, Brussels, Belgium
[5] Radboud Univ Nijmegen Med Ctr, Dept Radiol, Nijmegen, Netherlands
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70371-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
366
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
  • [1] A phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041)
    Heerschap, A.
    Fiedler, W.
    Marreaud, S.
    van Laarhoven, H.
    Govaerts, A.
    Peters, M.
    Toma, S.
    Bordignon, C.
    Punt, K.
    Van Herpen, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] A biological and pharmacologic phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041).
    Van Herpen, Carla
    Fiedler, Walter
    Marreaud, Sandrine
    Van Laarhoven, Hanneke
    Peters, Marlies
    Govaerts, Anne-Sophie
    Toma, Salvatore
    Bordignon, Claudio
    Heerschap, Arend
    Punt, Kees
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3457S - 3457S
  • [3] Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041)
    van Laarhoven, H.
    Fiedler, W.
    Desar, I. M.
    van Asten, S.
    Marreaud, S.
    Belli, R.
    Bordignon, C.
    Heerschap, A.
    Punt, C. J.
    van Herpen, C. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours
    Citterio, G.
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Noberasco, C.
    Boselli, S.
    Giovannini, M.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 129 - 129
  • [5] Both NGR and TNF portions contribute to the biological activity of NGR-TNF vascular targeting agent in vivo
    Alberici, Luca
    Valentinis, Barbara
    Porcellini, Simona
    Di Matteo, Paola
    Cota, Manuela
    Zhou, Dan
    Doglioni, Claudio
    Bordignon, Claudio
    Traversari, Catia
    Rizzardi, Gian-Paolo
    CANCER RESEARCH, 2011, 71
  • [6] Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF
    Paola Di Matteo
    Patrizia Mangia
    Elena Tiziano
    Barbara Valentinis
    Simona Porcellini
    Claudio Doglioni
    Francesca Sanvito
    Claudio Bordignon
    Gian-Paolo Rizzardi
    Catia Traversari
    Clinical & Experimental Metastasis, 2015, 32 : 289 - 300
  • [7] Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF
    Di Matteo, Paola
    Mangia, Patrizia
    Tiziano, Elena
    Valentinis, Barbara
    Porcellini, Simona
    Doglioni, Claudio
    Sanvito, Francesca
    Bordignon, Claudio
    Rizzardi, Gian-Paolo
    Traversari, Catia
    CLINICAL & EXPERIMENTAL METASTASIS, 2015, 32 (03) : 289 - 300
  • [8] Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors
    Gregorc, Vanesa
    De Braud, Filippo G.
    De Pas, Tommaso M.
    Scalamogna, Roberto
    Citterio, Giovanni
    Milani, Alessandra
    Boselli, Sabrina
    Catania, Chiara
    Donadoni, Giovanni
    Rossoni, Gilda
    Ghio, Domenico
    Spitaleri, Gianluca
    Ammannati, Cristina
    Colombi, Scialini
    Caligaris-Cappio, Federico
    Lambiase, Antonio
    Bordignon, Claudio
    CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1964 - 1972
  • [9] Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours
    P A Zucali
    M Simonelli
    F De Vincenzo
    E Lorenzi
    M Perrino
    M Bertossi
    R Finotto
    S Naimo
    L Balzarini
    C Bonifacio
    I Timofeeva
    G Rossoni
    G Mazzola
    A Lambiase
    C Bordignon
    A Santoro
    British Journal of Cancer, 2013, 108 : 58 - 63
  • [10] NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells
    Di Matteo, P.
    Hackl, C.
    Jedeszko, C.
    Valentinis, B.
    Bordignon, C.
    Traversari, C.
    Kerbel, R. S.
    Rizzardi, G-P
    BRITISH JOURNAL OF CANCER, 2013, 109 (02) : 360 - 369
12345